Methods for the treatment of a central nervous system injury via a tapered administration protocol
The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior to termination of administration of the progestin or progestin metabolite the administration is tapered to avoid withdrawal. The drug taper employed can involve a linear taper, an exponential taper, progressively dividing administered doses by 50%, or can be determined based on the treating physician's assessment of the patient's response to therapy. The tapered administration methods of the present invention may be used in combination with any therapeutic protocol or regimen for the administration of a therapeutically effective amount of a progestin or progestin metabolite to treat a traumatic or ischemic CNS injury.
1. A method of treating a traumatic brain injury, said method comprising administering a therapeutically effective amount of progesterone to a subject in need thereof, wherein prior to termination of administration of progesterone, said administration comprises a tapered administration dosing regimen.
2. The method of claim 1 , wherein said traumatic brain injury results from a blunt force contusion.
3. The method of claim 1 , wherein said tapered administration dosing regimen comprises progressively administering 50% divided doses of progesterone.
4. The method of claim 1 , wherein said tapered administration dosing regimen comprises a linear taper.
5. The method of claim 4 , wherein said linear taper is a 10% linear taper.
6. The method of claim 1 , wherein said tapered administration dosing regimen comprises an exponential taper.
7. The method of claim 1 , wherein said tapered administration dosing regimen is used in combination with administration of progesterone at least once a day.
8. The method of claim 1 , wherein said therapeutically effective amount of progesterone administered to said subject prior to the tapered administration dosing regimen comprises a constant progesterone dosing regimen.
9. The method of claim 1 , wherein said therapeutically effective amount of progesterone administered to said subject prior to the tapered administration dosing regimen comprises a two-level progesterone dosing regimen.
10. The method of claim 1 , wherein said tapered administration dosing regimen is carried out over a period of about 24 hours.
11. The method of claim 1 , wherein said tapered administration dosing regimen is carried out over a period of about 48 hours.
12. The method of claim 1 , wherein said tapered administration dosing regimen comprises a series of tapered doses.
13. The method of claim 4 , wherein said linear taper is a 25% linear taper.
14. The method of claim 4 , wherein said linear taper is a 50% linear taper.
15. The method of claim 1 , wherein said tapered administration is effected over a period of about 24 hours and comprises a series of doses tapered at a 25% linear taper.
16. The method of claim 1 , wherein the pharmaceutical composition is administered by a route selected from the group consisting of oral, vaginal, rectal, topical, nasal, ophthalmic, and parenteral.
17. The method of claim 16 , wherein the pharmaceutical composition is administered by a route selected from the group consisting of systemic, intraperitoneal, intravenous (IV), intramuscular (IM), subcutaneous (SC), transdermal, buccal, and intracerebroventricular.
18. The method of claim 16 , wherein the pharmaceutical composition is in a form selected from the group consisting of a solid, a particulant, a powder, a solution, a suspension, and an emulsion.